Oculis Receives EMA PRIME Designation for Privosegtor
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 9 hours ago
0mins
Should l Buy OCS?
Source: Newsfilter
- PRIME Designation Granted: Oculis's Privosegtor has received PRIME designation from the EMA, underscoring its potential in treating optic neuritis, particularly in providing significant therapeutic advantages where no effective treatments currently exist.
- Clinical Trial Success: In the Phase 2 ACUITY trial, Privosegtor demonstrated substantial improvements in low-contrast visual acuity, along with anatomical and biological neuroprotective benefits, reinforcing its potential as a neuroprotective treatment that could transform the management of optic neuritis.
- Significant Market Opportunity: The treatment market for optic neuritis presents a potential opportunity of $7 billion in the U.S. alone, and as the first neuroprotective therapy, Privosegtor is poised to address this critical unmet medical need, likely attracting considerable market interest.
- Advancing Global Registration Plans: Oculis is advancing its PIONEER registration program, which includes global registrational trials for optic neuritis and non-arteritic anterior ischemic optic neuropathy (NAION), expected to accelerate Privosegtor's clinical development and enhance its competitive positioning in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OCS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OCS
Wall Street analysts forecast OCS stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 24.550
Low
29.00
Averages
40.00
High
55.00
Current: 24.550
Low
29.00
Averages
40.00
High
55.00
About OCS
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oculis Receives EMA PRIME Designation for Privosegtor
- PRIME Designation Granted: Oculis's Privosegtor has received PRIME designation from the EMA, underscoring its potential in treating optic neuritis, particularly in providing significant therapeutic advantages where no effective treatments currently exist.
- Clinical Trial Success: In the Phase 2 ACUITY trial, Privosegtor demonstrated substantial improvements in low-contrast visual acuity, along with anatomical and biological neuroprotective benefits, reinforcing its potential as a neuroprotective treatment that could transform the management of optic neuritis.
- Significant Market Opportunity: The treatment market for optic neuritis presents a potential opportunity of $7 billion in the U.S. alone, and as the first neuroprotective therapy, Privosegtor is poised to address this critical unmet medical need, likely attracting considerable market interest.
- Advancing Global Registration Plans: Oculis is advancing its PIONEER registration program, which includes global registrational trials for optic neuritis and non-arteritic anterior ischemic optic neuropathy (NAION), expected to accelerate Privosegtor's clinical development and enhance its competitive positioning in the market.
See More
Oculis Secures PRIME Designation for Privosegtor, Advancing Development
- Regulatory Support Strengthened: Oculis's Privosegtor has received PRIME designation from the EMA, following the FDA's Breakthrough Therapy designation, indicating its potential in treating optic neuritis and possibly accelerating its global development process.
- Clinical Trial Results Promising: The ACUITY Phase 2 trial demonstrated significant improvements in low-contrast visual acuity with Privosegtor combined with steroids, reinforcing its efficacy as a neuroprotective treatment and addressing urgent needs for optic neuritis patients.
- Significant Market Opportunity: The potential market opportunity for optic neuritis is estimated at $7 billion, and as the first neuroprotective therapy, Privosegtor could fill this gap, meeting the current lack of effective treatments.
- Global Registration Program Advancing: Oculis is advancing the PIONEER registration program, which includes three global registrational trials in optic neuritis and non-arteritic anterior ischemic optic neuropathy, further validating Privosegtor's clinical application potential.
See More
Oculis Announces Upcoming Investor Conference Schedule
- Breakthrough Therapy Progress: Oculis' Privosegtor has received breakthrough therapy designation for optic neuritis (ON), which is expected to drive its strategic transformation in neuro-ophthalmology and tap into a market opportunity exceeding $7 billion in the U.S.
- Clinical Trial Advancements: The topline results for OCS-01 from the DIAMOND Phase 3 trials are anticipated in Q2 2026, positioning this non-invasive eye drop as a potential first registered treatment for diabetic macular edema (DME), thereby solidifying Oculis' leadership in ophthalmology.
- Precision Medicine Development: Licaminlimab is being evaluated in a registrational trial as the first genotype-based program for dry eye disease (DED), aiming to enhance personalized treatment options and strengthen Oculis' competitive edge in the ophthalmic market.
- Investor Conference Schedule: Oculis will present its innovative portfolio at several investor conferences in March, with CEO Riad Sherif scheduled to present on March 10, which is expected to attract investor interest in its robust clinical pipeline and financial health.
See More
Oculis Reports 2025 Financial Results and Clinical Milestones
- Narrowed Q4 Loss: Oculis reported a net loss of 23.51 million Swiss Francs in Q4 2025, or 0.42 Franc per share, down from 28.66 million Francs or 0.67 Franc per share last year, indicating improved cost management efforts.
- Expanded Annual Loss: The full-year net loss for 2025 increased to 98.96 million Francs, or 1.89 Franc per share, compared to 85.78 million Francs and 2.12 Franc per share in 2024, reflecting heightened R&D expenditures and intensified market competition.
- Increased Cash Reserves: As of December 31, 2025, the company reported cash and short-term investments of $268.7 million, significantly up from $109.0 million last year, providing a cash runway into 2029 to support ongoing operations.
- Clinical Trial Progress: The Phase 3 trials for OCS-01 are nearing completion with readouts expected in Q2 2026, and if positive, a New Drug Application to the FDA is planned for Q4 2026, with a potential market opportunity exceeding $30 billion.
See More
Oculis Holding Reports Q4 Earnings Beat Expectations
- Earnings Beat: Oculis Holding reported a Q4 GAAP EPS of CHF -0.42, surpassing expectations by $0.11, indicating potential improvements in profitability and investor confidence.
- Significant Revenue Growth: The operating income for Q4 reached CHF 411K, a substantial increase from CHF 3K in Q4 2024, reflecting strong market demand and sales performance.
- FDA Breakthrough Therapy Status: The company received FDA breakthrough therapy designation for its optic neuritis treatment, which could expedite the product's market entry and provide new revenue growth opportunities.
- Increased Investor Attention: Oculis's presentation at the 44th Annual J.P. Morgan Healthcare Conference garnered significant investor interest, further enhancing market confidence in its future prospects.
See More
Oculis Appoints New Chief Legal Officer to Enhance Leadership
- Leadership Enhancement: Oculis has appointed Katie Kazem as Chief Legal Officer, leveraging her extensive experience in life sciences to advance the company's three late-stage assets toward clinical and regulatory milestones.
- Legal Compliance Expertise: With over 15 years of experience in capital markets and corporate governance, Kazem has advised numerous public life sciences companies, which is expected to enhance Oculis's ability to navigate complex transactions and regulatory matters.
- Accelerated Clinical Progress: Oculis's Privosegtor project is advancing in the PIONEER program, which is expected to support registration trials for a novel neuroprotective platform, further solidifying its market position in neuro-ophthalmology.
- Deepening Strategic Collaboration: Kazem has served as external legal counsel since Oculis's NASDAQ listing in 2023, and will continue to work closely with the management team to drive rapid progress in clinical and commercialization efforts.
See More
Oculis Receives EMA PRIME Designation for Privosegtor
- PRIME Designation Granted: Oculis's Privosegtor has received PRIME designation from the EMA, underscoring its potential in treating optic neuritis, particularly in providing significant therapeutic advantages where no effective treatments currently exist.
- Clinical Trial Success: In the Phase 2 ACUITY trial, Privosegtor demonstrated substantial improvements in low-contrast visual acuity, along with anatomical and biological neuroprotective benefits, reinforcing its potential as a neuroprotective treatment that could transform the management of optic neuritis.
- Significant Market Opportunity: The treatment market for optic neuritis presents a potential opportunity of $7 billion in the U.S. alone, and as the first neuroprotective therapy, Privosegtor is poised to address this critical unmet medical need, likely attracting considerable market interest.
- Advancing Global Registration Plans: Oculis is advancing its PIONEER registration program, which includes global registrational trials for optic neuritis and non-arteritic anterior ischemic optic neuropathy (NAION), expected to accelerate Privosegtor's clinical development and enhance its competitive positioning in the market.
See More
Oculis Secures PRIME Designation for Privosegtor, Advancing Development
- Regulatory Support Strengthened: Oculis's Privosegtor has received PRIME designation from the EMA, following the FDA's Breakthrough Therapy designation, indicating its potential in treating optic neuritis and possibly accelerating its global development process.
- Clinical Trial Results Promising: The ACUITY Phase 2 trial demonstrated significant improvements in low-contrast visual acuity with Privosegtor combined with steroids, reinforcing its efficacy as a neuroprotective treatment and addressing urgent needs for optic neuritis patients.
- Significant Market Opportunity: The potential market opportunity for optic neuritis is estimated at $7 billion, and as the first neuroprotective therapy, Privosegtor could fill this gap, meeting the current lack of effective treatments.
- Global Registration Program Advancing: Oculis is advancing the PIONEER registration program, which includes three global registrational trials in optic neuritis and non-arteritic anterior ischemic optic neuropathy, further validating Privosegtor's clinical application potential.
See More
Oculis Announces Upcoming Investor Conference Schedule
- Breakthrough Therapy Progress: Oculis' Privosegtor has received breakthrough therapy designation for optic neuritis (ON), which is expected to drive its strategic transformation in neuro-ophthalmology and tap into a market opportunity exceeding $7 billion in the U.S.
- Clinical Trial Advancements: The topline results for OCS-01 from the DIAMOND Phase 3 trials are anticipated in Q2 2026, positioning this non-invasive eye drop as a potential first registered treatment for diabetic macular edema (DME), thereby solidifying Oculis' leadership in ophthalmology.
- Precision Medicine Development: Licaminlimab is being evaluated in a registrational trial as the first genotype-based program for dry eye disease (DED), aiming to enhance personalized treatment options and strengthen Oculis' competitive edge in the ophthalmic market.
- Investor Conference Schedule: Oculis will present its innovative portfolio at several investor conferences in March, with CEO Riad Sherif scheduled to present on March 10, which is expected to attract investor interest in its robust clinical pipeline and financial health.
See More
Oculis Reports 2025 Financial Results and Clinical Milestones
- Narrowed Q4 Loss: Oculis reported a net loss of 23.51 million Swiss Francs in Q4 2025, or 0.42 Franc per share, down from 28.66 million Francs or 0.67 Franc per share last year, indicating improved cost management efforts.
- Expanded Annual Loss: The full-year net loss for 2025 increased to 98.96 million Francs, or 1.89 Franc per share, compared to 85.78 million Francs and 2.12 Franc per share in 2024, reflecting heightened R&D expenditures and intensified market competition.
- Increased Cash Reserves: As of December 31, 2025, the company reported cash and short-term investments of $268.7 million, significantly up from $109.0 million last year, providing a cash runway into 2029 to support ongoing operations.
- Clinical Trial Progress: The Phase 3 trials for OCS-01 are nearing completion with readouts expected in Q2 2026, and if positive, a New Drug Application to the FDA is planned for Q4 2026, with a potential market opportunity exceeding $30 billion.
See More
Oculis Holding Reports Q4 Earnings Beat Expectations
- Earnings Beat: Oculis Holding reported a Q4 GAAP EPS of CHF -0.42, surpassing expectations by $0.11, indicating potential improvements in profitability and investor confidence.
- Significant Revenue Growth: The operating income for Q4 reached CHF 411K, a substantial increase from CHF 3K in Q4 2024, reflecting strong market demand and sales performance.
- FDA Breakthrough Therapy Status: The company received FDA breakthrough therapy designation for its optic neuritis treatment, which could expedite the product's market entry and provide new revenue growth opportunities.
- Increased Investor Attention: Oculis's presentation at the 44th Annual J.P. Morgan Healthcare Conference garnered significant investor interest, further enhancing market confidence in its future prospects.
See More
Oculis Appoints New Chief Legal Officer to Enhance Leadership
- Leadership Enhancement: Oculis has appointed Katie Kazem as Chief Legal Officer, leveraging her extensive experience in life sciences to advance the company's three late-stage assets toward clinical and regulatory milestones.
- Legal Compliance Expertise: With over 15 years of experience in capital markets and corporate governance, Kazem has advised numerous public life sciences companies, which is expected to enhance Oculis's ability to navigate complex transactions and regulatory matters.
- Accelerated Clinical Progress: Oculis's Privosegtor project is advancing in the PIONEER program, which is expected to support registration trials for a novel neuroprotective platform, further solidifying its market position in neuro-ophthalmology.
- Deepening Strategic Collaboration: Kazem has served as external legal counsel since Oculis's NASDAQ listing in 2023, and will continue to work closely with the management team to drive rapid progress in clinical and commercialization efforts.
See More
